the Efficacy and Safety of Agomelatine in the Patients With Parkinson's Disease
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Among the patients with Parkinson's disease, about 40%~50% will suffer from depression, 40%
will suffer from anxiety, and 40%~60% will suffer from sleep disorder. These non-motor
symptoms of Parkinson's disease will cause great physical and psychological pain and affect
the quality of life seriously. Commonly used therapeutic drugs, such as selective serotonin
reuptake inhibitor (SSRI) and clonazepam, can cause a variety of side effects, including
serotonin syndrome, sexual dysfunction, daytime fatigue, insomnia, residual effects and
increased risk of falls. Therefore, a new and more reasonable therapeutic choice should be
sought. Agomelatine is a new type of antidepressant with novel mechanism, and can improve
sleep structure and circadian rhythm. The aim of this multi-center randomized controlled
trial (RCT) is to clarify the role of agomelatine in improving sleep disorders and depression
in patients with Parkinson's disease